Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 November 16, 2026 LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update September 3, 2026 LeonaBio to Participate in Cantor Global Healthcare Conference 2026 August 14, 2026 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update August 12, 2026 LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer June 4, 2026 LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit May 27, 2026 LeonaBio to Participate in Upcoming Medical and Industry Meetings in June May 7, 2026 LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update May 7, 2026 LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. April 23, 2026 LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer April 21, 2026 Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 160
Year None 2026 2025 2024 2023 2022 2021 2020 2019 November 16, 2026 LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update September 3, 2026 LeonaBio to Participate in Cantor Global Healthcare Conference 2026 August 14, 2026 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update August 12, 2026 LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer June 4, 2026 LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit May 27, 2026 LeonaBio to Participate in Upcoming Medical and Industry Meetings in June May 7, 2026 LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update May 7, 2026 LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. April 23, 2026 LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer April 21, 2026 Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 160